Patents by Inventor Geraldine C. B. Harriman

Geraldine C. B. Harriman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CCR9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20100280074
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: December 3, 2009
    Publication date: November 4, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen
  • CCR9 inhibitors and methods of use thereof
    Patent number: 7820717
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: October 26, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C. B. Harriman, Zhan Shi, Shaowu Chen
  • CCR1 ANTAGONISTS AND METHODS OF USE THEREFOR
    Publication number: 20100249174
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Application
    Filed: April 22, 2010
    Publication date: September 30, 2010
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • CCR1 antagonists and methods of use therefor
    Patent number: 7732459
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: June 8, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • CCR9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20100093802
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 15, 2010
    Applicant: Millennnium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen
  • CCR9 inhibitors and methods of use thereof
    Patent number: 7659272
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: February 9, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C. B. Harriman, Zhan Shi, Chen Shaowu
  • CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
    Publication number: 20090281081
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Application
    Filed: May 6, 2009
    Publication date: November 12, 2009
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 7541365
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: June 2, 2009
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • CCR9 inhibitors and methods of use thereof
    Publication number: 20090054495
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: October 16, 2008
    Publication date: February 26, 2009
    Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen
  • CCR1 antagonists and methods of use therefor
    Publication number: 20080139602
    Abstract: The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compounds to a subject in need thereof. The disclosed compounds have CCR1 antagonist activity.
    Type: Application
    Filed: September 13, 2007
    Publication date: June 12, 2008
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, Geraldine C. B. Harriman, Shomir Ghosh
  • CCR9 inhibitors and methods of use thereof
    Patent number: 7282502
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: October 16, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C. B. Harriman, Zhan Shi, Chen Shaowu
  • Chemokine receptor antagonists and methods of use thereof
    Patent number: 7271176
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: September 18, 2007
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • CCR9 inhibitors and methods of use thereof
    Patent number: 7238717
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: July 3, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C. B. Harriman, Zhan Shi, Shaowu Chen
  • Chemokine receptor antagonists and methods of use thereof
    Patent number: 7186729
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: March 6, 2007
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Geraldine C. B. Harriman, Kenneth G. Carson, Shomir Ghosh, Amy M. Elder, Karen M. Mattia
  • Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
    Patent number: 6951848
    Abstract: Disclosed are novel compounds having the formula or a physiologically acceptable salt, amide, ester or prodrug thereof. The compounds can be used to modulate (antagonize, agonize) chemokine receptor function. Also disclosed is a method for treating a patient having an inflammatory disease and/or viral infection comprising administering an effective amount of a compound of Formula I. In particular embodiments, the invention is a method for treating a patient infected with HIV.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: October 4, 2005
    Assignee: Millennium Pharmaceuticals, Inc.,
    Inventors: Geraldine C. B. Harriman, Kenneth G. Carson, Daniel L. Flynn, Michael E. Solomon, Yuntao Song, Bharat K. Trivedi, Bruce D. Roth, Christine N. Kolz, Ly Pham, Kuai-lin Sun
  • CCR1 antagonists and methods of use therefor
    Publication number: 20040106639
    Abstract: The invention provides compounds having the formula: 1
    Type: Application
    Filed: November 12, 2003
    Publication date: June 3, 2004
    Applicant: Millennium Pharmaceuticals
    Inventors: Kenneth G. Carson, Geraldine C.B. Harriman
  • CCR9 inhibitors and methods of use thereof
    Publication number: 20040038976
    Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: May 21, 2003
    Publication date: February 26, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen
  • Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
    Publication number: 20030064991
    Abstract: Disclosed are novel compounds having the formula 1
    Type: Application
    Filed: March 12, 2002
    Publication date: April 3, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Geraldine C.B. Harriman, Kenneth G. Carson, Daniel L. Flynn, Michael E. Solomon, Yuntao Song, Bharat K. Trivedi, Bruce D. Roth, Christine N. Kolz, Ly Pham, Kuai-lin Sun
  • Chemokine receptor antagonists and methods of use therefor
    Publication number: 20030045516
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Application
    Filed: August 13, 2002
    Publication date: March 6, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Geraldine C. B. Harriman
  • Chemokine receptor antagonists and methods of use therefor
    Patent number: 6509346
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: January 21, 2003
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Geraldine C. B. Harriman